Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma

49 patients aged 28 to 81 years old (median age of 55 years old) with relapsed or refractory multiple myeloma (MM) were enrolled in the study. The relapse was diagnosed in 25 (51 %) patients, the refractory disease was determined in 24 (49 %) patients (including primary refractory disease in 14 (28....

Full description

Bibliographic Details
Main Authors: T. A. Мitinа, A. K. Golenkov, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, Yu. B. Chernykh, S. G. Zakharov, K. A. Belousov, A. V. Karaulov
Format: Article
Language:Russian
Published: ABV-press 2015-12-01
Series:Onkogematologiâ
Subjects:
multiple myeloma
revlimid
bortezomib
lenalidomide
prednisolone
refractory
relapse
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/162

Internet

https://oncohematology.abvpress.ru/ongm/article/view/162

Similar Items